The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2024 | Key considerations when referring a patient with CLL
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the referral process for patients with chronic lymphocytic leukemia (CLL). He recommends referring all patients with CLL, particularly those who have failed one or two lines of therapy, to centers of excellence. These centers provide access to newer treatments, such as CAR T-cell therapy, by enrolling patients in clinical trials. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
